5/13
01:12 am
valn
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine [Yahoo! Finance]
Low
Report
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine [Yahoo! Finance]
5/13
01:00 am
valn
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
Low
Report
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
5/8
08:08 am
valn
Valneva SE (NASDAQ: VALN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.
Low
Report
Valneva SE (NASDAQ: VALN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.
5/7
01:19 am
valn
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]
Neutral
Report
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]
5/7
01:00 am
valn
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Neutral
Report
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
5/5
02:55 am
valn
Vaccine Partners Turn Rivals With First Shot for Advancing Virus [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Vaccine Partners Turn Rivals With First Shot for Advancing Virus [Financial Post (Toronto, Ontario, Canada)]
5/5
02:48 am
valn
Vaccine Partners Turn Rivals With First Shot for Advancing Virus [BNN Bloomberg (Canada)]
Low
Report
Vaccine Partners Turn Rivals With First Shot for Advancing Virus [BNN Bloomberg (Canada)]
3/26
02:17 am
valn
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate [Yahoo! Finance]
Medium
Report
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate [Yahoo! Finance]
3/26
02:00 am
valn
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Medium
Report
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
3/25
02:06 am
valn
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F [Yahoo! Finance]
Low
Report
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F [Yahoo! Finance]
3/25
02:00 am
valn
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
Low
Report
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
3/22
02:32 pm
valn
Valneva SE (NASDAQ: VALN) had its price target lowered by analysts at Guggenheim from $18.00 to $17.00. They now have a "buy" rating on the stock.
Low
Report
Valneva SE (NASDAQ: VALN) had its price target lowered by analysts at Guggenheim from $18.00 to $17.00. They now have a "buy" rating on the stock.
3/21
11:19 am
valn
Valneva SE (NASDAQ:VALN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Valneva SE (NASDAQ:VALN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/21
08:06 am
valn
Valneva SE (NASDAQ: VALN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.
Low
Report
Valneva SE (NASDAQ: VALN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.
3/21
02:10 am
valn
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C. [Yahoo! Finance]
Low
Report
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C. [Yahoo! Finance]
3/21
02:00 am
valn
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.
Low
Report
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.
3/20
04:13 am
valn
Valneva GAAP EPS of -€0.73, revenue of €153.71M; updates FY24 guidance [Seeking Alpha]
High
Report
Valneva GAAP EPS of -€0.73, revenue of €153.71M; updates FY24 guidance [Seeking Alpha]
3/20
02:53 am
valn
French biotech company Valneva raises product sales guidance [Reuters]
High
Report
French biotech company Valneva raises product sales guidance [Reuters]
3/20
02:09 am
valn
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook [Yahoo! Finance]
High
Report
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook [Yahoo! Finance]
3/20
02:00 am
valn
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
High
Report
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
3/18
02:12 am
valn
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed [Yahoo! Finance]
Low
Report
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed [Yahoo! Finance]
3/18
02:00 am
valn
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
Low
Report
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
3/4
01:08 am
valn
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences [Yahoo! Finance]
Low
Report
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences [Yahoo! Finance]
3/4
01:00 am
valn
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
Low
Report
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
2/29
03:42 pm
valn
Valneva SE (NASDAQ: VALN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.
Medium
Report
Valneva SE (NASDAQ: VALN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.